CureVac (NASDAQ:CVAC) Trading Down 7.2% - What's Next?

CureVac (NASDAQ:CVAC - Get Free Report)'s share price traded down 7.2% during trading on Monday . The stock traded as low as $2.72 and last traded at $2.77. 244,698 shares traded hands during trading, a decline of 70% from the average session volume of 816,234 shares. The stock had previously closed at $2.98.

Analyst Upgrades and Downgrades

Separately, JMP Securities reissued a "market outperform" rating and issued a $16.00 target price on shares of CureVac in a research report on Friday, February 14th.

CureVac Stock Performance

The business's 50-day simple moving average is $3.28 and its 200 day simple moving average is $3.18. The firm has a market cap of $579.85 million, a P/E ratio of 4.71 and a beta of 2.53. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. grew its stake in shares of CureVac by 25.0% during the 4th quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company's stock valued at $1,705,000 after purchasing an additional 100,000 shares during the period. Geode Capital Management LLC grew its position in CureVac by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock valued at $824,000 after buying an additional 22,491 shares during the period. BNP Paribas Financial Markets purchased a new stake in CureVac during the fourth quarter valued at approximately $585,000. Two Sigma Investments LP bought a new position in CureVac in the fourth quarter worth approximately $391,000. Finally, Jane Street Group LLC boosted its stake in shares of CureVac by 239.0% during the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock worth $235,000 after acquiring an additional 55,867 shares during the last quarter. Institutional investors own 17.26% of the company's stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.